Sicheniza Ross Friedman Ference Advises Cell Source Ltd. on Reverse Merger
NEW YORK, July 1, 2014 (GLOBE NEWSWIRE) —
New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Cell Source Limited (Israel) in a reverse merger transaction whereby Cell Source Inc., a Nevada based publicly traded company under the symbol “CLCS: OTCQB”, acquired 100% of the capital stock of Cell Source Limited, an Israeli biotechnology company engaged in developing cell therapy treatments.
This past February, Sichenzia Ross represented Cell Source Limited in a private placement transaction consisting of 4.8 million units of securities raising approximately $3.6 million. Each unit consisted of one share of common stock and one common stock purchase warrant.
The Sichenzia Ross Friedman Ference LLP team was led by partner Gregory Sichenzia, David Manno and associate Jay Yamamoto.
Sichenzia Ross Media Contact:
- Sichenzia Ross Ference LLP Represents Borqs Technologies, Inc. in $20 Million Private Placement - March 3, 2021
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $8.5 Million Underwritten Public Offering of American Depositary Shares of Medigus Ltd. - March 3, 2021
- Sichenzia Ross Ference LLP Represents SunHydrogen in $10.0 Million Registered Direct Offering - March 3, 2021